|
Dr. Jose Baselga is the Chairman of the Medical Oncology Service and Director of the Division of Medical Oncology, Hematology and Radiation Oncology at the Vall d'Hebron University Hospital in Barcelona, Spain and a Professor of Medicine at the Universidad Autonoma de Barcelona. He has made significant contributions to the clinical development of several approved targeted cancer therapies, including trastuzumab, cetuximab, gefitinib and erlotinib. Dr. Baselga also is actively engaged in research and development of new classes of cancer therapies, such as ras farnesyltransferase inhibitors, m-TOR inhibitors and a variety of antiangiogenic agents. In addition to his academic responsibilities, Dr. Baselga also is a member of the Editorial Boards for Cancer Cell, Clinical Cancer Research and Investigational New Drugs. He has published over 150 peer-reviewed articles, in addition to over 300 abstracts and book chapters. He holds leadership positions in a number of cancer research organizations, including Scientific Chairman of the Spanish Breast Cancer cooperative group (SOLTI), Member of the Scientific Advisory Committee of the Ludwig Institute for Cancer Research (LICR) and is the President-Elect of the European Society for Medical Oncology (ESMO). Dr. Baselga received his M.D. degree from the Universidad Autonoma of Barcelona in 1982. He performed internal medicine residencies at Vall d'Hebron University Hospital in Barcelona and at State University of New York. He completed a fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Center in New York, subsequently joining the institution's staff. | 